This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          

ATTUNE® Knee System four-year revision rate is lower than total knee class

DePuy Synthes, part of the Johnson & Johnson Family of Companies, has announced new ATTUNE® Knee implant survivorship data based on an Implant Summary Report obtained from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR).

The independent analysis of 10,605 ATTUNE Knee implantations, showed that the cumulative revision rate for the ATTUNE Knee is 1.3% at four years (98.7% implant survivorship at four years), compares favorably to the 1.9% cumulative revision rate (98.1% implant survivorship at four years) for the overall class of total knee replacement.1

Of the 10,605 ATTUNE Knees included in the analysis from the NJR, 46 required revision. Based on a separate analysis, the report concluded that 63 ATTUNE Knee revisions would be expected at four years – a difference that was statistically significant (p<0.05).1 The expected number of ATTUNE Knee revisions was calculated by the NJR based on duration of implantation, age group, gender and indications.

DePuy Synthes announced the four-year data in Vienna, coinciding with the 18th European Federation of the National Associations of Orthopaedics and Traumatology (EFORT) Congress. The full analysis, including a breakdown of the reasons for revision, is available on www.ProvingthePromise.com and can be accessed here.

This most recent analysis adds to the body of evidence on the positive performance of the ATTUNE Knee,” said Joshua Bridgens, DePuy Synthes Franchise Medical Director. “The information and data in this analysis, such as reasons for revision and preliminary findings on patient-reported outcomes, continue to validate the design principles and our expectations for the clinical performance of the ATTUNE Knee.”

NJR publishes an annual report including 1, 3 and 5-year outcome data; however, additional survivorship data is now also available more frequently to manufacturers who subscribe to the NJR’s Implant Summary Report service.

Also announced at EFORT was the launch of the first ATTUNE® Knee revision options, the ATTUNE Revision Fixed Bearing Tibial Base and the 14×50 mm Cemented Stem. The Tibial Base is designed to address a range of patient needs, from complex primary to partial revision of ATTUNE Primary Knees.

DePuy Synthes is committed to the continued evaluation of outcomes through its comprehensive ATTUNE Knee Evidence Generation Program that, in addition to national joint registries, gathers information from investigator-initiated studies, independent studies and company initiated studies. ATTUNE Knee clinical evidence to date is available on www.ProvingthePromise.com

Reference

  1. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Implant Summary Report for DePuy ATTUNE CR and ATTUNE PS. NJR Database extract April 7, 2017, pages 1-17. Licensed for use until April 19, 2018. Available at www.ProvingthePromise.com
x